Citations

Mayo Clinic

Showing 10 of 108602 citations.

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
Jang, Albert , Kendi, Ayse T, Jang, Albert , Kendi, A. Tuba , Sartor, Oliver

Therapeutic Advances in Medical Oncology | March 4, 2023 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/17588359231157632 | PMID 36895851 Get It

Metastatic prostate cancer continues to be an incurable disease. Despite all the novel therapies approved in the past two decades, overall patient outcomes remain relatively poor, and these patients die on a regular basis. Clearly, improvements in current therapies are needed. Prostate-specific membrane antigen (PSMA) is a target for prostate cancer given its increased expression on the surface of the prostate cancer cells. PSMA small molecule binders include PSMA-617 and PSMA-I&T and monoclonal antibodies such as J591. These agents have been linked to different radionuclides including beta-emitters such as lutetium-177 and alpha-emitters such as actinium-225. The only regulatory-approved PSMA-targeted radioligand therapy (PSMA-RLT) to date is lutetium-177–PSMA-617 in the setting of PSMA-positive metastatic castration-resistant prostate cancer that has failed androgen receptor pathway inhibitors and taxane chemotherapy. This approval was based on the phase III VISION trial. Many other clinical trials are evaluating PSMA-RLT in various settings. Both monotherapy and combination studies are underway. This article summarizes pertinent data from recent studies and provides an overview of human clinical trials in progress. The field of PSMA-RLT is rapidly evolving, and this therapeutic approach will likely play an increasingly important role in the years to come.
Systematic Transmission Electron Microscopy‐Based Identification and 3D Reconstruction of Cellular Degradation Machinery
Neikirk, Kit , Vue, Zer , Katti, Prasanna , Rodriguez, Ben I., Omer, Salem, Shao, Jianqiang, Christensen, Trace , Garza-López, Edgar , Marshall, Andrea G. , Palavicino‐Maggio, Caroline B. , Ponce, Jessica, Alghanem, Ahmad F. , Vang, Larry , Barongan, Taylor , Rodman, Taylor, Stephens, Dominique, Mungai, Margaret , Murray, Sandra , Crabtree, Amber , Pereira, Renata O. , Hinton, Antentor , Glancy, Brian , Abel, E Dale , Hinton, Antentor , Pereira, Renata O , Katti, Prasanna , Murray, Sandra A , Marshall, Andrea G , Beasley, Heather K. , Stephens, Dominique C., Correia, Marcelo , Exil, Vernat , Damo, Steven M. , Glancy, Brian , Abel, E. Dale

Advanced Biology | March 3, 2023 | Volume: 7 | Issue: 6 | Pages: No page available

10.1002/adbi.202200221 | PMID 36869426 Get It

Abstract Various intracellular degradation organelles, including autophagosomes, lysosomes, and endosomes, work in tandem to perform autophagy, which is crucial for cellular homeostasis. Altered autophagy contributes to the pathophysiology of various diseases, including cancers and metabolic diseases. This paper aims to describe an approach to reproducibly identify and distinguish subcellular structures involved in macroautophagy. Methods are provided that help avoid common pitfalls. How to distinguish between lysosomes, lipid droplets, autolysosomes, autophagosomes, and inclusion bodies are also discussed. These methods use transmission electron microscopy (TEM), which is able to generate nanometer‐scale micrographs of cellular degradation components in a fixed sample. Serial block face‐scanning electron microscopy is also used to visualize the 3D morphology of degradation machinery using the Amira software. In addition to TEM and 3D reconstruction, other imaging techniques are discussed, such as immunofluorescence and immunogold labeling, which can be used to classify cellular organelles, reliably and accurately. Results show how these methods may be used to accurately quantify cellular degradation machinery under various conditions, such as treatment with the endoplasmic reticulum stressor thapsigargin or ablation of the dynamin‐related protein 1.
Development of a Risk Stratification Model for Pre–liver-Transplant Screening Colonoscopy
Travers, Paul , Body, Ashton E., Palmer, William C. , Pang, Maoyin , Travers, Paul M , Cortés, Pedro

Journal of Clinical Gastroenterology | March 3, 2023 | Volume: 58 | Issue: 3 | Pages: 281-288

10.1097/mcg.0000000000001838 | PMID 36867500 Get It

Background and Aims: Colonoscopies are routinely obtained before liver transplantation, although their utility is a highly debated topic in the literature. We aimed to determine the risk factors in patients with decompensated cirrhosis (DC) for post-colonoscopy complications (PCC). Materials and Methods: We performed a single-center retrospective study of patients with DC undergoing colonoscopy as part of their pre–liver-transplant evaluation. The primary composite outcome was defined as a complication occurring within 30 days of the colonoscopy. Complications included acute renal failure, new or worsening ascites or hepatic encephalopathy, gastrointestinal bleeding, or any cardiopulmonary or infectious complication. Logistic regression analysis was utilized to derive a risk score in predicting the primary composite outcome. Results: The strongest predictors of post-colonoscopy complication were MELD-Na ≥21 [aOR 4.0026 (P=0.0050)] and history of any infection in the 30 days before colonoscopy [aOR 8.4345 (P=0.0093)]. The area under the receiver operating characteristic curve of the final model was 0.78. The predicted risk of any complication at the lowest quartile was 16.2% to 39.4%, and the observed risk was 30.6% (95% CI: 15.5-45.6%), while the predicted risk at the highest quartile was 71.9% to 97.1%, and the observed risk was 81.3% (95% CI: 67.7-95%). Conclusion: In this cohort of patients with DC undergoing colonoscopy for pre–liver-transplant evaluation, a history of ascites, spontaneous bacterial peritonitis, and MELD-Na were found to be predictive of PCC. This risk score may help to predict PCC in patients with DC undergoing a pre-transplant colonoscopy. External validation is recommended.
Neuropsychiatric Symptoms and Commonly Used Biomarkers of Alzheimer’s Disease: A Literature Review from a Machine Learning Perspective
Shah, Jay , Krell‐Roesch, Janina , Syrjanen, Jeremy A. , Kremers, Walter K. , Vassilaki, Maria , Forzani, Erica , Geda, Yonas E. , Krell-Roesch, Janina, Geda, Yonas E , Kremers, Walter K , Siddiquee, Md Mahfuzur Rahman , Wu, Teresa

Journal of Alzheimer's Disease | March 3, 2023 | Volume: 92 | Issue: 4 | Pages: 1131-1146

10.3233/jad-221261 | PMID 36872783 Get It

There is a growing interest in the application of machine learning (ML) in Alzheimer’s disease (AD) research. However, neuropsychiatric symptoms (NPS), frequent in subjects with AD, mild cognitive impairment (MCI), and other related dementias have not been analyzed sufficiently using ML methods. To portray the landscape and potential of ML research in AD and NPS studies, we present a comprehensive literature review of existing ML approaches and commonly studied AD biomarkers. We conducted PubMed searches with keywords related to NPS, AD biomarkers, machine learning, and cognition. We included a total of 38 articles in this review after excluding some irrelevant studies from the search results and including 6 articles based on a snowball search from the bibliography of the relevant studies. We found a limited number of studies focused on NPS with or without AD biomarkers. In contrast, multiple statistical machine learning and deep learning methods have been used to build predictive diagnostic models using commonly known AD biomarkers. These mainly included multiple imaging biomarkers, cognitive scores, and various omics biomarkers. Deep learning approaches that combine these biomarkers or multi-modality datasets typically outperform single-modality datasets. We conclude ML may be leveraged to untangle the complex relationships of NPS and AD biomarkers with cognition. This may potentially help to predict the progression of MCI or dementia and develop more targeted early intervention approaches based on NPS.
Current Practice of Sleep Medicine in Lebanon
Sabri, Alain Michel, Coussa-Koniski, Marie-Louise M. , Costanian, Christy

The Practice of Sleep Medicine Around The World: Challenges, Knowledge Gaps and Unique Needs | March 3, 2023 | Volume: No volume available | Issue: No issue available | Pages: 117-127

10.2174/9789815049367123010013 Get It

There are several major universities and medical schools in Lebanon, including the American University of Beirut School of Medicine &amp; Medical Center, Lebanese American University/Medical Center, Lebanese University, Universite Saint Joseph/Hotel Dieu de France, Beirut Arab University, University of Balamand, Saint Georges University/Medical Center, Holy Spirit University of Kaslik and others. Many of these medical centers and schools of medicine offer a solid medical education as well as post-graduate training in various fields of medicine that are related to sleep medicine. These include Pulmonary and Critical Care Medicine, General/Bariatric Surgery, Neurology, Otolaryngology, Head and Neck Surgery, Dentistry, Oral &amp; Maxillofacial Surgery, Orthodontics, Psychiatry, Nutrition/dietetics and other related specialties.<br><br>As will be further elaborated in this chapter, there are multiple particularities related to the diagnosis and management of patients who have sleep disorders in Lebanon. Even though the field is developing, there are certainly opportunities for further advancement and development.<br>
Preface
Sabri, Alain Michel

The Practice of Sleep Medicine Around The World: Challenges, Knowledge Gaps and Unique Needs | March 3, 2023 | Volume: No volume available | Issue: No issue available | Pages: i-i

10.2174/9789815049367123010001 Get It

4DCT is long overdue for improvement
Tryggestad, E., Li, Heng , Rong, Yi , Tryggestad, Erik, Rong, Yi

Journal of Applied Clinical Medical Physics | March 3, 2023 | Volume: 24 | Issue: 4 | Pages: No page available

10.1002/acm2.13933 | PMID 36866617 Get It

Autograft Demonstrates Superior Outcomes for Revision Anterior Cruciate Ligament Reconstruction When Compared With Allograft: A Systematic Review
Belk, John W. , Smith, John-Rudolph H. , McCarty, Eric C. , Kraeutler, Matthew J. , Smith, John R. , McCarty, Eric C , Smith, John-Rudolph , Littlefield, Connor P. , McCulloch, Patrick C. , Frank, Rachel M

The American Journal of Sports Medicine | March 3, 2023 | Volume: 52 | Issue: 3 | Pages: 859-867

10.1177/03635465231152232 | PMID 36867049 Get It

Background: Multiple studies have compared outcomes among patients undergoing revision anterior cruciate ligament reconstruction (ACLR) with autograft versus allograft, but these data are inconsistently reported and long-term outcomes depending on graft type are yet to be determined. Purpose: To perform a systematic review of clinical outcomes after revision ACLR (rACLR) with autograft versus allograft. Study Design: Systematic review; Level of evidence, 4. Methods: A systematic review of the literature was performed by searching PubMed, the Cochrane Library, and Embase to identify studies that compared the outcomes of patients undergoing rACLR with autograft versus allograft. The search phrase used was autograft allograft revision anterior cruciate ligament reconstruction. Graft rerupture rates, return-to-sports rates, anteroposterior laxity, and patient-reported outcome scores (subjective International Knee Documentation Committee, Tegner, Lysholm, and Knee injury and Osteoarthritis Outcome Score) were evaluated. Results: Eleven studies met inclusion criteria, including 3011 patients undergoing rACLR with autograft (mean age, 28.9 years) and 1238 patients undergoing rACLR with allograft (mean age, 28.0 years). Mean follow-up was 57.3 months. The most common autograft and allograft types were bone–patellar tendon–bone grafts. Overall, 6.2% of patients undergoing rACLR experienced graft retear, including 4.7% in the autograft group and 10.2% in the allograft group ( P < .0001). Among studies that reported return-to-sports rates, 66.2% of patients with an autograft returned to sports as opposed to 45.3% of patients with an allograft ( P = .01). Two studies found significantly greater postoperative knee laxity in the allograft group as compared with the autograft group ( P < .05). Among all patient-reported outcomes, 1 study found 1 significant difference between groups: patients with an autograft had a significantly higher postoperative Lysholm score when compared with patients with an allograft. Conclusion: Patients undergoing revision ACLR with an autograft can be expected to experience lower rates of graft retear, higher rates of return to sports, and less postoperative anteroposterior knee laxity when compared with patients undergoing revision ACLR with an allograft.
Primary Retinal Detachment Outcomes Study: summary of reports number 1 to number 18
Ryan, Edwin H. , Yonekawa, Yoshihiro , Starr, Matthew R.

Current Opinion in Ophthalmology | March 3, 2023 | Volume: 34 | Issue: 3 | Pages: 211-217

10.1097/icu.0000000000000942 | PMID 36866845 Get It

Purpose of review To highlight the recent work published from the Primary Retinal Detachment Outcomes (PRO) Study Group. Recent findings The PRO database was a large dataset made up of patients with primary rhegmatogenous retinal detachments (RRD) who had surgical repair during 2015. The database was constituted of nearly 3000 eyes from 6 centers across the United States and included 61 vitreoretinal surgeons. Nearly 250 metrics were collected for each patient, creating one of the richest datasets of patients with primary rhegmatogenous detachments and their outcomes. The importance of scleral buckling was demonstrated, particularly for phakic eyes, elderly patients, and those with inferior breaks. 360° laser may result in poorer outcomes. Cystoid macular edema was common, and risk factors were identified. We also found risk factors for vision loss in eyes presenting with good vision. A PRO Score was devised, to predict outcomes based on presenting clinical characteristics. We also identified characteristics of surgeons with the highest single surgery success rates. Overall, there were no major outcome differences between viewing systems, gauges, buckles sutured vs. scleral tunnels, drainage method, and techniques to address proliferative vitreoretinopathy. All incisional techniques were found to be very cost-effective treatment modalities. Summary Numerous studies resulted from the PRO database that significantly added to the literature regarding the repair of primary RRDs in the current era of vitreoretinal surgery.
Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder
Pittock, Sean J. , Barnett, Michael , Bennett, Jeffrey L. , Levy, Michael , Nakashima, Ichiro , Palace, Jacqueline , Paul, Friedemann , Yountz, Marcus, Allen, Kerstin , Mashhoon, Yasmin, Kim, Ho Jin, Palace, Jacqueline , Pittock, S J , Levy, Michael , Nakashima, Ichiro , Oreja-Guevara, Celia , Paul, Friedemann , Bennett, Jeffrey L , Palace, Jacqueline , Barnett, Michael H , Berthele, Achim , Seze, Jerome De , Oreja‐Guevara, Celia , Pozzilli, Carlo , Kim, Ho Jin

Annals of Neurology | March 3, 2023 | Volume: 93 | Issue: 6 | Pages: 1053-1068

10.1002/ana.26626 | PMID 36866852 Get It

Objective CHAMPION‐NMOSD (NCT04201262) is a phase 3, open‐label, externally controlled interventional study evaluating the efficacy and safety of the terminal complement inhibitor ravulizumab in adult patients with anti–aquaporin‐4 antibody–positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD). Ravulizumab binds the same complement component 5 epitope as the approved therapeutic eculizumab but has a longer half‐life, enabling an extended dosing interval (8 vs 2 weeks). Methods The availability of eculizumab precluded the use of a concurrent placebo control in CHAMPION‐NMOSD; consequently, the placebo group of the eculizumab phase 3 trial PREVENT (n = 47) was used as an external comparator. Patients received weight‐based intravenous ravulizumab on day 1 and maintenance doses on day 15, then once every 8 weeks. The primary endpoint was time to first adjudicated on‐trial relapse. Results The primary endpoint was met; no patients taking ravulizumab (n = 58) had an adjudicated relapse (during 84.0 patient‐years of treatment) versus 20 patients with adjudicated relapses in the placebo group of PREVENT (during 46.9 patient‐years; relapse risk reduction = 98.6%, 95% confidence interval = 89.7%–100.0%, p < 0.0001). Median (range) study period follow‐up time was 73.5 (11.0–117.7) weeks for ravulizumab. Most treatment‐emergent adverse events were mild/moderate; no deaths were reported. Two patients taking ravulizumab experienced meningococcal infections. Both recovered with no sequelae; one continued ravulizumab treatment. Interpretation Ravulizumab significantly reduced relapse risk in patients with AQP4+ NMOSD, with a safety profile consistent with those of eculizumab and ravulizumab across all approved indications. ANN NEUROL 2023;93:1053–1068